Drug industry proposes limits on advertising

Facing a reaction against consumer drug advertising, the pharmaceutical industry moved toward self-policing yesterday by releasing draft guidelines that endorse a period of informing doctors about new drugs before running ads for them. The guidelines, whose final wording is still being worked out, try to address growing pressure from a variety of fronts, including Capitol Hill and the American Medical Association, and even from within the industry itself. They may not satisfy consumer groups, however, who called the guidelines a gesture to placate Congress.

- read this story from The New York Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.